Weather forecast

Aardvark Therapeutics (AARD) stock forecast

Rainy

Sell

Score 32/100 · Confidence 70%

Clouds are gathering — better to let this weather pass.

Weighed fromlive price action

Why this call

A Debt-Free Bet on Future Drug Discovery

The prevailing negative price trend over the past month remains a headwind.

Lack of profits or revenue puts pressure on the stock's valuation.

Without positive news, the path of least resistance appears to be lower.

Where it's headed

Aardvark Therapeutics price targets

As of Jun 20, 2026, Tickerday rates Aardvark Therapeutics (AARD) a Sell, score 32/100, with 70% confidence. Each target is measured from $3.93, the price that day.

Next week

$4

+1.8% from $3.93

The stock may find some short-term support after a recent bounce from its lows, but high volatility makes its path unpredictable.

Next month

$3.70

−5.8% from $3.93

The broader downtrend is likely to overcome any minor bounces unless a significant positive catalyst emerges.

Next year

$3.25

−17.3% from $3.93

Over the long term, the fundamental uncertainty of its pre-revenue status outweighs the benefit of its debt-free balance sheet.

Share this forecastXRedditWhatsApp

Under the hood

What the engine weighed

Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.

32Overall score
Valuation
20

The company is not profitable, making traditional valuation metrics unusable and its worth highly speculative.

Growth
15

With no revenue reported, the company's growth is entirely dependent on future, uncertain clinical trial outcomes.

Profitability
10

The company is currently losing money as it invests in research and development, with negative earnings.

Momentum
15

The stock has been in a strong downtrend over the past year, trading near its 52-week low.

Fin. health
80

The company's balance sheet is a key strength, as it currently operates with no debt.

Sentiment
50

There has been no significant recent news to meaningfully shift market sentiment in either direction.

Key numbers

as of Jun 20, 2026

Size and price

Growth and profit

Risk and payout

The argument

Both sides of the sky

Every call has a case against it. Here's the honest version of both.

The bull case

  • The company is completely debt-free, which provides significant financial stability and reduces risk of bankruptcy.
  • As a small drug development company, any positive news from clinical trials could have a major impact on the stock price.
  • The stock is trading near its 52-week lows, which some investors might view as a potential entry point.

The bear case

  • The company is not profitable and has no revenue, making its valuation entirely speculative.
  • The stock price has fallen dramatically over the past year, indicating significant negative market momentum.
  • The stock is extremely volatile, meaning its price can swing sharply in either direction.

FAQ

Good questions

Tickerday's read of Aardvark Therapeutics as of Jun 20, 2026: educational analysis, the same for everyone, not financial advice.

Most tools hand you the data.
Tickerday hands you the answer.

Now try yours

What about your stocks?

You just read Aardvark Therapeutics. Type a company you own and get its call, and the why, in seconds. First one free, no account needed.

SearchApple

The receipts

Called it. Then it happened.

Real calls from the Tickerday engine, each one graded against the real price a month later.

Palantir Technologies Inc.

+52.3%

✓Called it

We said Buy at $122.33 on Jul 30. A month later the price was $186.29.

Graded Aug 28 at the closing price

Today's prices

Weather alerts

We'll watch the weather.You enjoy the day.

Save a stock to your Almanac. We'll track its forecast and let you know when the outlook changes.

Your Almanac

Watching 4 stocks

AARD

Aardvark Therapeutics

Sell

AAPL

Apple

Buy

MSFT

Microsoft

Buy

TSLA

Tesla

Sell

9:41

Thursday, October 16

9:41

Nothing to chase. Nothing to refresh.

Sunny under an umbrella

One blind call costs more
than a year of Tickerday.

Pricing

Start free, right here

Your first analysis is free, no account needed. Tickerday+ takes it from there.

Tickerday+

Pro

Built for fast clarity.

  • Clear buy / hold / sell-style insights
  • Key risks and opportunities
  • Focused market analysis
  • 40 priority credits every month
$9/mo

Billed monthly · ≈ $0.30/day

Tickerday+

Most popular

Premium

The full why, explained.

  • Expanded analysis & learning depth
  • Interactive explanations & breakdowns
  • Tap to understand key metrics & terms
  • 100 priority credits every month
$228 (was)$169/yrSAVE 26%

Billed yearly · ≈ $14.08/mo≈ $0.46/day

Cancel anytime.

Sunny, Tickerday's mascot, fast asleep under the stars

Get the full picture

That took thirty seconds. Now imagine every stock you own.

You just understood AARD without reading a single chart. The Tickerday app does this for your whole watchlist — today's read whenever you want it, the full thesis, bull and bear scenarios with their odds — and wakes you the moment the weather turns.

One plain answer for every stock — Buy, Hold, or Sell

The full picture in seconds — thesis, targets & scenarios

Sleep easy — we watch the market and wake you if it turns

Free to download the day it lands — the web desk is open now

More forecasts

More lists